ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1496
CHEMBL1496
Compound Name ROSUVASTATIN
ChEMBL Synonyms ROSUVASTATIN | S-4522 | ROSUVASTATIN CALCIUM | ZD-4522 | CRESTOR | ZD4522 (CALCIUM SALT)
Max Phase 4 (Approved)
Trade Names CRESTOR
Molecular Formula C22H28FN3O6S

Additional synonyms for CHEMBL1496 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(C)c1nc(nc(c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N ...
Download SMILES
Standard InChI InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-1 ...
Download InChI
Standard InChI Key BPRHUIZQVSMCRT-VEUZHWNKSA-N

Sources

  • BindingDB Database
  • British National Formulary
  • Gene Expression Atlas Compounds
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1496

Molecule Features

CHEMBL1496 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
HMG-CoA reductase inhibitor HMG-CoA reductase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
LIPID METABOLISM DISORDERSD052439Orphanet:309005DISORDER OF LIPID METABOLISM1ClinicalTrials
HYPERCHOLESTEROLEMIAD006937HP:0003124HYPERCHOLESTEROLEMIA3ClinicalTrials
HYPERLIPOPROTEINEMIA TYPE IID006938EFO:0004911FAMILIAL HYPERCHOLESTEROLEMIA3ClinicalTrials

Clinical Data

ClinicalTrials.gov ROSUVASTATIN
The Cochrane Collaboration ROSUVASTATIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1496. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
481.5 481.1683 2.43 10 149.29 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
8 3 0 9 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.25 - .89 -2.24 2 33 0.47

Structural Alerts

There are 2 structural alerts for CHEMBL1496. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C10 - LIPID MODIFYING AGENTS
C10A - LIPID MODIFYING AGENTS, PLAIN
C10AA - HMG CoA reductase inhibitors
C10AA07 - rosuvastatin

ChemSpider ChemSpider:BPRHUIZQVSMCRT-VEUZHWNKSA-N
DailyMed rosuvastatin calcium
Wikipedia Rosuvastatin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1496



Atlas Rosuvastatin
BindingDB 18372
Brenda 8562
ChEBI 38545
DrugBank DB01098
DrugCentral 2406
eMolecules 877496
EPA CompTox Dashboard DTXSID8048492
FDA SRS 413KH5ZJ73
Guide to Pharmacology 2954
Human Metabolome Database HMDB15230
IBM Patent System B0E78E11E390F832E3994E0C365BE7E3
LINCS LSM-43032
MolPort MolPort-000-883-884
Nikkaji J3.118.169K
PharmGKB PA134308647
PubChem 446157
PubChem: Thomson Pharma 14834808 14810118
SureChEMBL SCHEMBL2520
ZINC ZINC000001535101

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/BPRHUIZQVSMCRT-VEUZHWNKSA-N spacer
spacer